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Abstract: 
 
Selenium is a trace element essential to human health largely because of its incorporation into 
selenoproteins that have a wide range of protective functions. Selenium has an ongoing history 
of reducing the incidence and severity of various viral infections; for example, a German study 
found selenium status to be significantly higher in serum samples from surviving than non-
surviving COVID-19 patients. Furthermore, a significant, positive, linear association was found 
between the cure rate of Chinese patients with COVID-19 and regional selenium status. 
Moreover, the cure rate continued to rise beyond the selenium intake required to optimise 
selenoproteins, suggesting that selenoproteins are probably not the whole story. Nonetheless, the 
significantly reduced expression of a number of selenoproteins, including those involved in 
controlling ER stress, along with increased expression of IL-6 in SARS-CoV-2 infected cells in 
culture suggests a potential link between reduced selenoprotein expression and COVID-19-
associated inflammation. In this comprehensive review, we describe the history of selenium in 
viral infections and then go on to assess the potential benefits of adequate and even supra-
nutritional selenium status. We discuss the indispensable function of the selenoproteins in 
coordinating a successful immune response and follow by reviewing cytokine excess, a key 
mediator of morbidity and mortality in COVID-19, and its relationship to selenium status. We 
comment on the fact that the synthetic redox-active selenium compound, ebselen, has been found 
experimentally to be a strong inhibitor of the main SARS-CoV-2 protease that enables viral 
maturation within the host. That finding suggests that redox-active selenium species formed at 
high selenium intake might hypothetically inhibit SARS-CoV-2 proteases. We consider the 
tactics that SARS-CoV-2 could employ to evade an adequate host response by interfering with 
the human selenoprotein system. Recognition of the myriad mechanisms by which selenium 
might potentially benefit COVID-19 patients provides a rationale for randomised, controlled 
trials of selenium supplementation in SARS-CoV-2 infection. 
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A B S T R A C T   
Selenium is a trace element essential to human health largely because of its incorporation into selenoproteins 
that have a wide range of protective functions. Selenium has an ongoing history of reducing the incidence and 
severity of various viral infections; for example, a German study found selenium status to be significantly higher 
in serum samples from surviving than non-surviving COVID-19 patients. Furthermore, a significant, positive, 
linear association was found between the cure rate of Chinese patients with COVID-19 and regional selenium 
status. Moreover, the cure rate continued to rise beyond the selenium intake required to optimise selenoproteins, 
suggesting that selenoproteins are probably not the whole story. Nonetheless, the significantly reduced 
expression of a number of selenoproteins, including those involved in controlling ER stress, along with increased 
expression of IL-6 in SARS-CoV-2 infected cells in culture suggests a potential link between reduced selenoprotein 
expression and COVID-19-associated inflammation. In this comprehensive review, we describe the history of 
selenium in viral infections and then go on to assess the potential benefits of adequate and even supra-nutritional 
selenium status. We discuss the indispensable function of the selenoproteins in coordinating a successful immune 
response and follow by reviewing cytokine excess, a key mediator of morbidity and mortality in COVID-19, and 
its relationship to selenium status. We comment on the fact that the synthetic redox-active selenium compound, 
ebselen, has been found experimentally to be a strong inhibitor of the main SARS-CoV-2 protease that enables 
viral maturation within the host. That finding suggests that redox-active selenium species formed at high sele-
nium intake might hypothetically inhibit SARS-CoV-2 proteases. We consider the tactics that SARS-CoV-2 could 
employ to evade an adequate host response by interfering with the human selenoprotein system. Recognition of 
the myriad mechanisms by which selenium might potentially benefit COVID-19 patients provides a rationale for 
randomised, controlled trials of selenium supplementation in SARS-CoV-2 infection.   
1. Introduction 
Selenium (Se) is a unique trace element; it is the only one of the trace 
elements to be specified in the genetic code. It is essential at a very low 
level of intake, from 55 to 75 μg/d [1,2], yet toxic above 800 μg/d, with 
the Safe Upper Limit being defined as 400 μg/d [1]. The essentiality of 
selenium is linked to the remarkable range of functions of the seleno-
proteins that are described below [3]. 
Selenium gets into the food chain through plants which take it up 
from the soil. The amount taken up is dependent not only on the 
selenium content of the soil which relates to the underlying geology, but 
to soil pH, the presence of organic matter and climatic conditions [4]. 
The effect of climate is nicely exemplified by the selenium-poor belt in 
China where the selenium status is decisively affected by monsoonal 
precipitation [5]. 
An unusual aspect of selenium is the extremely wide range of intake 
seen across the globe (Supplemental Table 1 [6,7]); that in China varies 
from the lowest to the highest in the world. Intake currently ranges from 
14 μg/d in Mianning County, Sichuan Province which has a long history 
of selenium deficiency and was the site in 1974–1976 of a study showing 
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that selenium supplementation prevents Keshan disease [8], to 550 μg/d 
in Enshi County, Hubei Province (Supplemental Table 1 [6,7]). In the 
1960s, Se toxicity (selenosis) was prevalent in Enshi County and, as late 
as 1981, intake was reported to be as high as 4990 μg/d in some areas of 
Enshi [9]. 
With this remarkable degree of variation in intake, it is not surprising 
that there have been numerous examples of adverse health conditions 
linked to selenium deficiency including those caused by viruses [3,10] 
and also by selenium excess [11]. As with many nutrients, there is a 
U-shaped relationship between Se intake or status and its health effects; 
that relationship is particularly noticeable for selenium [11]. 
In this comprehensive review we will explore the evidence for the 
involvement of selenium, whether as particular selenium species or 
selenoproteins, in viral infections. We will first cover the important role 
Table 1 
Multiple selenoprotein functions relevant to viral infection.  
Selenoprotein function Selenoproteins that carry out those functions, 
with some examples 
Antioxidant The following selenoproteins have antioxidant 
functions: GPX1, GPX2, GPX3, GPX4, TXNRD1, 
TXNRD2, TXNRD3, MSRB1, SELENOP, 
SELENOW [3,14,15] 
GPX1 protects against Keshan Disease [16]. 
GPx1 Pro198Leu SNP affects risk of Kashin-Beck 
disease [17]. 
GPX4 rs713041 SNP affects risk of pre-eclampsia 
[18]. 
GPX4 reduces lipid peroxides accumulated 
during ferroptosis into non-toxic lipid alcohols 
[19]. 
Redox function; maintaining 
cellular redox homeostasis 
TXNRD1 required for DNA synthesis [20]. 
TXNRD1 maintains redox tone in immune cells 
through regeneration of reduced cytosolic TXN1 
[15]. 
TXNRD2 preserves mitochondrial integrity, 
redox homeostasis and cardiac function in the 
ageing heart [21]. 
Anti-inflammatory Selenoproteins: 
–produce anti-inflammatory lipid mediators from 
arachidonic acid to protect cells against pro- 
inflammatory gene expression induced by 
oxidative stress [14,22] 
–increase the production of 15d-PGJ2 decreasing 
activation of NF-κB and down- regulating 
inflammatory-gene expression [14,22] 
–activate PPAR-γ, repressing inflammatory gene 
expression [14,22] 
GPXs: metabolise ROS to prevent activation of 
NF-κB, its translocation to the nucleus and its 
binding to pro-inflammatory cytokine genes 
[23]. 
TXNRD1: induces haem oxidase-1 which has 
anti-inflammatory functions linked to its removal 
of the pro-oxidant, haem, its production of the 
antioxidant biliverdin and the vasodilatory, anti- 
inflammatory carbon monoxide [22,24]. 
SELENOS: reduces inflammation by removing 
misfolded proteins from the ER, protecting from 
the unfolded protein response [25]. See data on 
SELENOS SNPs –rs28665122 (autoimmune 
thyroid disease, pre-eclampsia) [26,27]; 
rs8025174 (CHD); rs7178239 (ischemic stroke) 
[28]. 
Immune-cell function Selenoproteins: 
– regulate inflammation and immunity, being 
linked to redox signalling, oxidative burst, 
calcium flux, and the subsequent effector 
functions of immune cells [15] 
– induce up-regulation of the IL-2 receptor 
increasing the ability of T and B lymphocytes to 
respond to IL-2, and augmenting immune-cell 
function [29]. 
GPXs, TXNRDs and MSRB1 maintain redox tone 
or reverse oxidative damage inflicted on immune 
cells, for instance, from their own respiratory- 
burst reaction [15]. 
SELENOK is required for the ER associated 
protein degradation (ERAD) pathway and 
regulation of Ca2+ flux from the ER. Several 
immune cell functions rely on efficient store 
operated Ca2+ entry (SOCE) and are 
compromised in SELENOK deficient immune 
cells; these include proliferation, migration, 
cytokine secretion and protection against 
pathogens [15,30]. 
SELENOS mitigates ER stress arising from 
increased protein processing that accompanies 
macrophage activation [15,30]. 
SELENOS affects circulating levels of 
inflammatory cytokines (IL-1β, IL-6, TNF-α)  
Table 1 (continued ) 
Selenoprotein function Selenoproteins that carry out those functions, 
with some examples 
involved in Hashimoto’s Thyroiditis 
pathogenesis [25,26]. 
GPX3 removes excessive H2O2, protecting 
against autoimmune thyroid disease 
(Hashimoto’s Thyroiditis, HT) [31]. 
GPX4 plays an essential role in T cell immunity 
by preventing ferroptotic cell death [32]. 
Antiviral effects Se/selenoproteins such as GPXs, TXNRDs and 
ER selenoproteins influence viral 
pathogenicity, partly by reducing oxidative stress 
generated by viral pathogens as shown in the 
following viral infections: coxsackievirus B3, 
Influenza A/Bangkok/1/79 (H3N2), Influenza 
H1N1, HIV-1, Polio, Hepatitis B & C, Hantavirus 
[33]. Inability to counteract oxidative stress can 
result in mutations in the viral genome from 
benign to highly virulent [16,33]. 
TXNRD1 is critical for expansion of the activated 
T-cell population during infection with 
lymphocytic choriomeningitis virus (LCMV)-WE 
strain [20]. 
GPX1 (Pro198Leu) polymorphism is implicated 
in the severity of liver fibrosis and hepatocellular 
carcinoma caused by hepatitis C virus [34]. 
Selenoproteins can be encoded in the viral 
genome, e.g. in Molluscum Contagiosum & 
Fowlpox, presumably protecting them against 
ROS produced by host phagocytes [33]. 
NF-κB is activated by multiple families of viruses, 
promoting viral replication and preventing virus- 
induced apoptosis [35]. By increasing the 
production of 15d-PGJ2, Se/selenoproteins can 
decrease activation of NF-κB, reducing viral 
replication [14]. 
Transport SELENOP transports Se from liver to tissues 
including brain, testes and placenta [36]. 
Protection of the cardiovascular 
system 
GPX1: protects against cardiomyopathy in 
Keshan Disease [16]; higher GPX1 activity 
significantly reduced the risk of a cardiovascular 
event in patients with coronary artery disease 
[37]. 
GPX1 198Pro/Leu variant genotype significantly 
associated with coronary artery disease risk in a 
Chinese population [38]. 
GPX4: individuals with the C718T TT genotype 
have impaired endothelial function and greater 
risk of vascular disease [39]. 
TXNRD2: preserves mitochondrial integrity, 
redox homeostasis, and cardiac function in the 
ageing heart [21]. 
Se = selenium; GPX1, GPX2, GPX3, GPX4 = cytosolic, gastrointestinal, extra-
cellular, phospholipid glutathione peroxidases, respectively; TXNRD1, TXNRD2, 
TXNRD3 = cytosolic, mitochondrial, testis thioredoxin reductases, respectively; 
MSRB1 = methionine sulfoxide reductase B1; SELENOP = selenoprotein P; 
SELENOK = selenoprotein K; SELENOW = selenoprotein W; PPAR-γ = Peroxi-
some proliferator-activated nuclear receptor-γ; IKKβ = IκB-kinase β. 
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of the selenoproteins in combatting viral infection. We will then describe 
the evidence for the effects of selenium/selenoproteins on viral patho-
genicity, including data that link them with SARS-CoV-2/COVID-19. We 
will discuss the effect of selenium/selenoproteins on immunity and 
production of inflammatory cytokines and will touch on the possible 
viral targeting of selenoprotein mRNAs by antisense and related mech-
anisms. We will then consider potential mechanisms by which selenium 
species, including selenoproteins, might affect COVID-19 outcome, 
mentioning specifically the synthetic selenium compound, ebselen, and 
redox-active selenium species. We will finish by discussing whether 
selenium supplementation might potentially benefit SARS-CoV-2 infec-
ted individuals, and if so, what the relevant dose might be. 
2. The selenoproteins 
All the selenoproteins contain selenocysteine at their active centre 
and are synthesised by a complex process [12]. In the presence of a 
selenocysteine insertion sequence (SECIS) in the 3′-untranslated region 
of mRNA, the UGA codon, which normally acts as a stop codon, is 
recoded to specify the insertion of selenocysteine [12]. A number of 
other factors are also required before selenocysteine can be incorporated 
into the growing protein chain [12]. The human genome contains 25 
genes that encode selenoproteins. These selenoproteins have a wide 
range of functions, from antioxidant and anti-inflammatory roles to the 
production of active thyroid hormone [12,13]. Many selenoprotein 
genes are polymorphic; where the genotype of a particular poly-
morphism (or SNP) affects the risk of a health condition, we know that 
the function of that selenoprotein is relevant to that condition [3]. 
2.1. Selenoprotein functions relevant to viral infection 
Selenoprotein functions known to be relevant to viral infection are 
shown in Table 1. From the table, it is clear that there are many ways in 
which selenium, via selenoprotein functions, might counteract infection 
with SARS-CoV-2. 
2.2. Effect of SARS-CoV-2 on selenoprotein expression 
There is already some evidence for a link between SARS-CoV-2 
infection and selenoproteins; infection of cultured Vero E6 cells with 
SARS-CoV-2 significantly reduced the expression of a number of 
selenoproteins (GPX4, TXNRD3, and the endoplasmic reticulum sele-
noproteins, SELENOS, SELENOK, SELENOF, SELENOM) while 
increasing the expression of the inflammatory cytokine, IL-6 [40]. 
Concomitant down-regulation of SELENOF, SELENOM, SELENOK and 
SELENOS by SARS-CoV-2 is likely to result in increased concentration of 
misfolded proteins in the ER and catastrophic ER stress. A direct 
mechanistic link between the reduced expression of SELENOS and the 
production of inflammatory cytokines has already been well docu-
mented [25]; such a mechanism may be relevant to the marked eleva-
tion of IL-6 concentration induced by SARS-CoV-2. 
3. Selenium status and viral pathogenicity 
Significant clinical benefits of selenium supplementation have been 
demonstrated in a number of viral infections, as previously reviewed 
[33,41,42]. These include most notably, coxsackievirus B3 and Keshan 
Disease, a cardiomyopathy named after the area in north-east China 
where it was endemic [16]; when the population was supplemented 
with selenium enabling adequate synthesis of the antioxidant GPX1 to 
occur, the incidence of Keshan Disease fell from 11.2 cases/1000 to 0.6 
cases/1000 [3,43]. In a series of clever experiments, Beck and 
co-workers showed that in mice that were unable to make sufficient 
GPX1, both coxsackievirus B3 and influenza A/Bangkok/1/79 (H3N2) 
mutated into more virulent forms that caused more severe disease or 
death [16]. Some other examples of the effects of selenium are in HIV-1, 
where a negative correlation between selenium status and mortality has 
been established [3,44], in hepatitis B linked to liver cancer [45], and in 
patients with hantavirus (“epidemic hemorrhagic fever”) who were 
successfully treated with oral sodium selenite, giving an overall 80% 
reduction in mortality [46]. From the above data it seems clear that 
selenium intake or status is relevant to infection with a number of 
evolutionarily distinct viruses and that selenium deficiency can influ-
ence viral mutation and evolution [16]. 
Factors associated with COVID-19-related death include male sex, 
age, deprivation, ethnicity, obesity, diabetes, severe asthma and other 
chronic diseases [47]. With regard to sex, there appear to be key dif-
ferences in the baseline immune capabilities in men and women during 
the early phase of SARS-COV-2 infection, with female patients mounting 
significantly more robust T-cell activation than male patients [48]. 
However, it is the case that a number of these factors, most notably age, 
obesity and chronic disease, for instance, chronic obstructive pulmonary 
Fig. 1. Correlation between COVID-19 cure rate in 17 
cities outside Hubei on Feb 18, 2020, and city population 
selenium status (hair selenium concentration) analysed 
using weighted linear regression. Each data point repre-
sents the cure rate, calculated as percentage of patients 
hospitalized with SARS-CoV-2 deemed to be cured*. The 
size of the marker is proportional to the number of cases 
(adapted from Am J Clin Nutr [7] with permission). From 
the graph of Se intake vs hair Se concentration, Supple-
mental Figure 1, Seintake = 232.98 Sehair – 44.521,allow-
ing the calculation of corresponding values of selenium 
intake and hair concentration (Supplemental Table 3). 
Thus value A represents the hair concentration corre-
sponding to an intake of 55 µg/d where platelet GPX1 
activity is maximised [58], value B represents the hair 
concentration corresponding to an intake of 105 µg/d 
where SELENOP concentration is maximised [58], and 
value C is the hair selenium concentration (1.0 mg/kg) at 
the maximum cure rate in the investigated cities which 
corresponds to an intake of 188 µg/d.*Cured patients are 
those in whom temperature has returned to normal for more 
than 3 days, respiratory symptoms are significantly 
improved, lung imaging shows significant reduction of 
inflammation, negative nucleic acid test of respiratory path-
ogen on two consecutive occasions with a sampling interval of 
at least 1 day.   
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disorder (COPD), also have a negative effect on selenium status [47, 
49–51], suggesting that such patients might benefit from nutritional 
levels of selenium supplementation. However, the low selenium status 
linked to these conditions may well be a by-product of the associated 
inflammation [52–54] and factors other than selenium are likely to be 
much more relevant. 
The most recent example of the relevance of selenium to viral dis-
eases is our analysis of the COVID-19 cumulative data on the specific 
date of February 18, 2020 in Chinese cities [7]. On inspection of the data 
from Hubei province where the first cases were reported, it was notable 
that the cure rate in Enshi city, renowned for its high selenium intake 
(550 μg/d in 2013 [55]), at 36.4%, was much higher than that of other 
Hubei cities where the overall cure rate was 13.1%; indeed, the Enshi 
cure rate was significantly different from that in the rest of Hubei (p <
0.0001) [7]. Similar inspection of data from provinces outside Hubei 
showed that Heilongjiang Province in north-east China, a notoriously 
low-selenium region (intake 16 μg/d in 2018 [56]), had a much higher 
death rate, at 2.4%, than that of other provinces (0.5%); p < 0.0001 [7]. 
When we plotted the cure rate in cities outside Hubei province against 
population selenium status, as measured by hair selenium concentration 
(a validated measure of selenium intake [57]), we found a significant 
linear association; R2 = 0.72, F-test p < 0.0001 [7] (Fig. 1). 
We were interested to see what range of selenium intake was rep-
resented by the hair-selenium concentrations in Fig. 1, so we searched 
the literature for data on selenium intake that had corresponding values 
of hair-selenium concentration (see Supplemental Table 2). The 
regression of selenium intake against hair selenium (Supplemental Fig. 
1) enabled us to determine the hair-selenium concentration corre-
sponding to an intake of 55 μg/d, at which platelet GPX1 activity is 
maximised [58], i.e. 0.43 mg/kg (see Supplemental Table 3). We simi-
larly determined the hair selenium concentration corresponding to an 
intake of 105 μg/d at which SELENOP concentration is optimised, i.e. 
64 mg/kg [58]. Interestingly, there is no sign of a plateau in Fig. 1 at 
either of those hair-selenium concentration values. Indeed, the cure rate 
continues to rise above those points, reaching the high end of the 
regression line at a cure rate of 56% and hair-selenium concentration of 
1.0 mg/kg, corresponding to an intake of 188 μg/d (see Supplemental 
Table 3) suggesting that selenoproteins are unlikely to be the whole 
story. 
Some readers may question why, if COVID-19 outcome is related to 
selenium status, we have not seen better disease outcomes in countries 
with higher selenium status, such as the USA, Canada and Japan, than in 
countries of Europe that generally have lower status. While acknowl-
edging differences in a number of factors that vary between countries 
including rate of testing, demographics and healthcare-system charac-
teristics, as already pointed out by Seale and colleagues [59], countries 
with the highest reported COVID-19 case-fatality rates [60] correspond 
to those where suboptimal selenium status has previously been docu-
mented [6,61]. Thus, mean (SD) case-fatality rates in Italy, France, 
Spain and the United Kingdom were recorded by the Johns Hopkins 
Coronavirus Resource Centre as 13.4 (2.1)% [corresponding to a mean 
(SD) intake of 56 (8) μg/d] on July 28, 2020 whereas the corresponding 
value in the United States, Canada and Japan where the populations are 
selenium adequate, was substantially lower, at 4.8 (2.5)% [corre-
sponding to a mean (SD) intake of 128 (46) μg/d] (see Supplemental 
Table 1) [6,60]. As to why we saw an apparently unique association 
between selenium status and COVID-19 cure-rate in Chinese cities, it 
may relate to the fact that the maximum and minimum selenium intakes 
in China are more widely separated, at 14 and 550 μg/d, than intakes 
elsewhere in the world [7]. 
Reinforcing our observed association between selenium status and 
outcome of COVID-19 disease is a German study that found a pro-
nounced deficit in total serum selenium and SELENOP concentrations in 
COVID-19 patients when compared with reference data from the large 
European EPIC cross-sectional study [62]. Selenium status below the 
2.5th percentile of the reference population was present in 43.4% 
(selenium) and 39.2% (SELENOP) of COVID patient serum samples. 
Furthermore, selenium status was significantly higher in samples from 
surviving COVID patients than from non-survivors (selenium, 53.3 ±
16.2 vs. 40.8 ± 8.1 μg/L; SELENOP, 3.3 ± 1.3 vs. 2.1 ± 0.9 mg/L) [62]. 
As this is an observational study, it cannot show causality; the low se-
lenium status associated with severity could reflect reduced expression 
of SELENOP by inflammatory cytokines under acute-phase conditions 
[62]. However, the exceptionally low level of serum selenium reached 
will inevitably have adverse effects on the concentration of protective 
selenoproteins which, according to Moghaddam and colleagues [62], 
argues for the potential relevance of some supplemental selenium sup-
port in severe COVID disease. One might speculate that such low sele-
nium status in severe COVID-19 disease could potentially be linked via 
reduced selenoprotein deiodinase activity to the low thyroid function 
(serum total tri-iodothyronine) observed in COVID patients that corre-
lated significantly with disease severity [63]. 
4. Potential mechanisms by which selenium species could affect 
SARS-CoV-2 or COVID-19 
We have presented above the evidence that shows an association 
between selenium species and SARS-CoV-2 or COVID-19 disease. While 
there is as yet no evidence for causality, there are a number of plausible 
mechanisms by which selenium, in one or other of its forms, could affect 
the virus and indeed vice-versa. These will be explored below beginning 
with immune system effects. 
4.1. The immune system in COVID-19 
Our understanding of the full role the immune system plays in 
COVID-19 is still developing; however, there is mounting evidence that 
excessive innate responses and cytokine release contribute to morbidity 
and mortality. It has been noted that severe disease correlates with tissue 
accumulation of macrophages and the production of the inflammatory 
cytokines IL-1β, IL-6, and TNF-α [64]. “Functional exhaustion” of nat-
ural killer (NK) Cells and cytotoxic T-cells has also been identified as a 
factor in severe COVID-19 [65]. 
Several features of severe COVID-19 display signs of immunological 
dysfunction – namely lymphopenia, high levels of inflammatory cyto-
kines and monocytic invasion of pulmonary tissue [66]. Curiously, 
simultaneous occurrences of immunological diseases in patients with 
COVID-19 are surfacing, indicating disarray in both adaptive and hu-
moral immunity. These include cases of the Anti-Phospholipid Syn-
drome (APLS) [67], five documented cases of Guillain-Barré Syndrome 
(GBS) [68] and a case of Immune Thrombocytopenia Purpura (ITP), that 
appeared to be directly triggered by the SARS-COV-2 virus [69]. 
Furthermore, some of the rashes apparent in COVID-19 patients have a 
resemblance to those associated with immune-complex deposition, such 
as chilblains and livedo reticularis [70]. 
Selenium supplementation has been noted to stimulate T-cell pro-
liferation and enhance innate immune-system functions [71]. Supple-
mentation of 200 μg/day (as sodium selenite) for 8 weeks caused large 
increases in cytotoxic T cells and Natural Killer (NK) cells by upregu-
lating receptors for the growth regulatory lymphokine, interleukin-2 
and consequently, the rate of cell proliferation and differentiation into 
cytotoxic cells [72]. One trial revealed enhancement of NK cells 
following selenium supplementation [73]. It follows that the “functional 
exhaustion” of such cells in severe COVID-19 disease may represent a 
reversible attenuation of selenoprotein function. 
Selenium deficiency, on the other hand, seems to favour a particular 
balance of Th1:Th2 responses, that can be modified towards a pre-
dominant Th1 phenotype by supra-nutritional selenium supplementa-
tion [15]. This may be due to an increase in levels of free thiols following 
selenium supplementation and improved T-cell proliferation, which 
fosters a phenotypically different inflammasome [74]. This may be a 
crucial insight, as it has been shown that cytokine release varies 
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significantly depending on the T-helper phenotype response in infection 
with respiratory-syncytial virus in children [75]. In selenium-replete 
individuals, Th1 predominance following polio immunisation 
signalled a more “robust” response to the vaccine [76]. 
These effects seem most striking in the elderly, who we know are 
overrepresented in COVID-19 mortality figures [47]. One randomised 
trial revealed significant increases in CD4 (+) T Cells, following pro-
longed supplementation with 400 μg selenium/day in elderly volunteers 
[77]. This indicates that the elderly, in particular, can have striking 
variations in their immunophenotype, which can be modulated by 
external factors such as selenium intake. 
The effect that selenium may have on Th1:Th2 ratios needs further 
investigation; while a Th1 phenotype can be beneficial in developing 
cellular immunity, it is also associated with many of the cytokines that 
correlate with COVID-19 severity [78]. Whether selenium supplemen-
tation can promote a Th1 response that results in a beneficial cellular 
response without contributing to further inflammation, remains to be 
seen. 
Within the innate immune system, selenium supplementation has 
been shown to affect macrophage responses, shifting them away from a 
“pro-inflammatory” reaction with regard to cytokine release [79]. In 
mice inoculated with Influenza A, selenium deficiency led to higher 
rates of macrophage infiltration of the lungs than in selenium-replete 
mice [80]. In one recent murine study, selenium deficiency was shown 
to inhibit macrophage phagocytosis directly and promote NF-κB-me-
diated inflammation [81]. 
4.2. Effect of selenium on inflammatory cytokine release 
A cytokine storm has been identified as a pathogenic mechanism for 
the deterioration of critically ill patients with COVID-19 by careful ex-
amination of circulating cytokines [82]; in particular, the cytokines 
IL-1β and IL-6 have been recognised as leading to lung inflammation 
[83]. Accordingly, IL-6 levels were noted to be higher in patients with 
severe disease than in those with mild disease [84] and high IL-6 levels 
positively correlated with severe disease [83]. In previous models of 
pneumonia, mortality has also been shown to be associated with high 
IL-6 levels [85]. IL-6 is an inflammatory cytokine that plays a central 
role in the coordination of innate and adaptive immunity. Its inhibition 
has been central to the management of various manifestations of the 
cytokine storm [86]. Elevation of IL-6 was associated with mortality in 
infection with the similar coronavirus, MERS-CoV, responsible for 
Middle East Respiratory Syndrome (MERS) [87]. 
There are multiple ongoing trials regarding the use of Tocilizumab (a 
humanised monoclonal antibody which binds soluble and membrane- 
bound IL-6 receptors) in COVID-19 and some promising results, albeit 
in small groups, have been shown as reviewed by Zhang et al. [88]. 
Hydroxychloroquine, a drug that has been investigated in COVID-19, is 
also known to modulate the cytokine response and reduce IL-6 levels 
[89], though recent observational studies have not identified a clear 
benefit in COVID-19 [90]. 
Selenium has been found to downregulate the IL-6 response [43,54] 
and selenium deficiency has been noted to be associated with higher 
levels of IL-6 in the elderly [91]. In vitro, bronchial epithelial cells 
infected with Influenza A grown in selenium-deficient conditions had 
increased IL-6 production [92]. Induction of IL-6 in mice placed under 
oxidative stress was prevented by selenium supplementation [93]. 
Similarly, selenium-deficient mice infected by the bacterium Listeria 
monocytogenes had significantly higher circulating IL-6 levels than 
infected controls [94]. In a different murine trial, however, selenium 
adequacy led to higher levels of IL-6 in healthy mice [95]. This may 
indicate that an adequate level of selenium contributes to optimal levels 
of IL-6, both in health and disease, though further investigation is 
warranted. 
IL-6 is a well-established surrogate for chronic inflammation in 
prostate cancer and inversely correlates with tumour response to 
chemotherapy [96]. In such cases, it has been shown that IL-6 levels can 
be reduced by sodium selenite supplementation [97]. In liver cirrhosis, 
subsequent to alcoholic liver disease, serum selenium concentration was 
inversely correlated with serum IL-6 [98]. One large review detailed an 
increase in inflammatory cytokines in the gastrointestinal system 
resulting from selenium deficiency [99]. In inflammatory bowel disease 
(IBD), selenium deficiency exacerbates colitis, as reviewed by Kudva 
et al. [100]. In acute myeloid and lymphoblastic leukaemias (AML and 
ALL), the rates of oral mucositis, following hematopoietic stem-cell 
transplantation (HSCT) in selenium-supplemented patients were 
significantly reduced compared to those of placebo controls in a rand-
omised controlled trial [101]. Though, in this case there was no signif-
icant difference in the circulating cytokine levels, it was concluded that 
selenium had offset parts of the inflammatory cascade. 
In Kashin-Beck disease, increased levels of IL-6, IL-1β and TNF-α 
were found in selenium-depleted individuals [102]. In a systematic re-
view of 32 studies of autoimmune diseases, such as rheumatoid arthritis 
and vasculitis, significantly lower serum selenium concentration was 
identified in cases than in controls [103], though the direction of cau-
sality was unclear. 
In critically ill patients with sepsis, selenium concentrations were 
noted to be low, and oxidative damage was higher than in replete pa-
tients [104]. Most suggestively, in a study of critically ill patients with 
Acute Respiratory Distress Syndrome (ARDS), selenium significantly 
“restored the antioxidant capacity of the lungs, moderated the inflam-
matory responses, and meaningfully improved the respiratory me-
chanics” [105]. No discernible survival benefit was appreciated, 
however, in that study. 
The above examples appear to demonstrate that higher selenium 
status, or selenium supplementation, reduces the level of inflammatory 
cytokines; this observation requires an attempt to explain the mecha-
nism which we have attempted to do below. 
4.3. Selenoproteins in cytokine regulation 
The activation of inflammatory cytokines, including IL-6, is coordi-
nated by the transcription factor NF-κB, which has been shown to be 
specifically inhibited by selenite in cell culture studies [106]. Further-
more, IL-6 downregulates hepatic biosynthesis of a number of seleno-
proteins [43,54]. Hydrogen peroxide, lipid and phospholipid 
hydroperoxides are ROS that are reduced by the GPX family to harmless 
water or alcohols, thus reducing oxidative stress. Unregulated ROS 
production may activate NF-κB and promote excessive cytokine release 
[107] as well as specifically contributing to the pathogenesis of 
COVID-19-related acute respiratory distress syndrome (ARDS), by 
increasing the tendency for thrombotic micronangiopathy [108]. As 
NF-κB is crucial for transcription of inflammatory cytokines associated 
with severe COVID-19 [109], further trials are needed to elucidate 
whether selenium supplementation can downregulate NF-κB expression 
in vivo and indeed whether this confers a survival benefit. 
Lastly, as further evidence for the importance of selenium in cytokine 
regulation, one selenoprotein gene (SELENOS), has a particular 105G/A 
promoter polymorphism (rs28665122), known to be strongly associated 
with circulating levels of inflammatory cytokines, especially IL-1β, IL-6, 
and TNF-α [25]. 
Examples in the literature have delineated a clear role for selenium in 
the regulation of inflammatory cytokines and implicated selenium 
deficiency in the pathogenesis of inflammatory states. Whether these 
findings reflect a hidden variable correlating with both is unestablished; 
however, a clear inverse correlation between selenium status and IL-6 
levels has been demonstrated. 
4.4. Viral targeting of selenoprotein mRNAs by antisense and related 
mechanisms 
There are several possible viral mechanisms that could directly affect 
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the host selenoproteome, thereby indirectly modifying the pool of 
redox-active selenium metabolites and contributing to the observed 
clinical benefits of selenium in certain viral infections. One is the pos-
sibility of virally-encoded glutathione peroxidases (vGPX), which would 
directly compete with the host for limited pools of selenocysteine in 
infected cells. As reviewed by Guillin et al. [33], vGPX have been 
demonstrated in both DNA and RNA viruses. The precedent of an HIV-1 
encoded plasma GPX homologue [110–112] is particularly relevant for 
other RNA viruses like SARS-CoV-2, because current evidence suggests 
that the putative selenocysteine-encoding UGA codon in the viral mRNA 
is recoded using a SECIS element hijacked from a TXNRD1 mRNA that is 
captured via a virus/host RNA/RNA-antisense tethering interaction 
[41]. That microRNA-like interaction is very likely to lead additionally 
to knockdown of TXNRD1 protein synthesis, which is consistent with the 
substantial decrease in 75Se-labeled TXNRD1 protein levels observed in 
HIV-1 infected cells [113]. 
Computational and in vitro evidence support the possibility of similar 
antisense targeting of TXNRD mRNAs by a number of RNA viruses 
([114] and references therein). In some cases, including HIV-1 and Ebola 
Zaire (EBOV), these interaction sites are associated with highly 
conserved UGA stop codons that terminate known viral open reading 
frames (HIV-1 nef, EBOV nucleoprotein), and so may be serving the 
function of SECIS capture via antisense tethering for the synthesis of 
viral selenoprotein modules [41,114,115]. In other cases (e.g. Zika 
virus, mumps virus and some pathogenic strains of avian influenza), 
there is no evidence of viral selenoprotein encoding, so the antisense 
interaction appears to serve some other function, for which the most 
obvious hypothesis involves the role of TXNRD in DNA synthesis [114, 
116]. Just as some large DNA viruses encode their own ribonucleotide 
reductase to increase DNA synthesis for virus production, some RNA 
viruses may attempt to boost RNA synthesis by inhibiting the diversion 
of ribonucleotides for DNA synthesis, for which thioredoxin serves as an 
electron donor for ribonucleotide reductase, which thus in turn requires 
TXNRD for sustained conversion of ribonucleotides to 
deoxyribonucleotides. 
Based on computational analysis, like EBOV and mumps virus, SARS- 
CoV-2 appears to target TXNRD3 via antisense at several sites, and the 
quality of the interactions (22 base pairs over a range of 23 or 24 bases) 
is similar to that of the strongest microRNA interactions [114]. This 
suggests a probable knockdown of TXNRD3 at both the mRNA and 
protein levels, which has been validated in a recent study showing that 
TXNRD3 mRNA is decreased by about 37% in SARS-CoV-2 infected Vero 
cells [40]. Although TXNRD3 mRNA levels are highest in the testes, 
according to the Human Protein Atlas [117], TXNRD3 protein levels are 
as high or higher in the lung and GI tract, which are major sites of 
SARS-CoV-2 replication. Significantly, the ACE2 receptor used by 
SARS-CoV-2 is also expressed at high levels in the testes. Testicular 
mumps infection is classic, and EBOV infection of the testes is now un-
derstood to be a major cause of persistent infection [118]. Because of the 
high levels of ACE2 receptor there, SARS-CoV-2 could also target the 
testes. So all three of these TXNRD3-targeting viruses appear to at least 
have the potential to infect the tissue in which TXNRD3 is most highly 
expressed in human males [114]. 
A similar viral mechanism that is at least theoretically possible is the 
targeting of host selenoproteins for degradation by proteolysis, 
achieving a similar result as antisense knockdown, but by a different 
mechanism. Targeting of host proteins by viral proteases is a well- 
documented phenomenon but has until now never been observed vs. a 
host selenoprotein. However, the recent demonstration of a high quality 
protein-protein interaction between an inactive C145A mutant of the 
SARS-CoV-2 main cysteine protease, Mpro, and human GPX1 [119], 
although rather paradoxical because of the failure to observe any 
interaction between wild type Mpro and GPX1, raises the possibility that 
GPX1 may be a substrate for Mpro, and that the products of proteolytic 
cleavage had disassociated from the active enzyme prior to detection. 
This interpretation is strengthened by the identification of potential Mpro 
cleavage site sequences in GPX1 as well as in TXNRD1 and SELENOF, 
with the latter being essentially identical to a known Mpro cleavage site 
over a span of 8 residues [120]. Proteolytic targeting of SELENOF would 
complement its 76% knockdown at the mRNA level by SARS-CoV-2, 
suggesting that the viral agenda is significantly enhanced by interfer-
ence in the function of this particular selenoprotein. 
The location of the predicted Mpro cleavage site in TXNRD1, five 
residues from its C-terminal, would remove its selenocysteine- 
containing redox centre, making it incapable of regenerating reduced 
thioredoxin [120]. Along with the demonstrated knockdown of TXNRD3 
at the mRNA level, this outcome is consistent with the hypothesis that 
SARS-CoV-2 may be actively inhibiting DNA synthesis, which would 
result in the increased availability of ribonucleotides for viral RNA 
synthesis [114,120]. Taken together, these proposed mechanisms, tar-
geting selenoproteins at both the mRNA and protein levels, would 
represent an unprecedented frontal assault on selenoprotein biosyn-
thesis by a pathogen, and suggest a potentially significant role of sele-
nium status in the pathogenesis of COVID-19. 
4.5. SARS-CoV-2 main protease as a target for inhibition: effectiveness of 
selenium-containing ebselen 
The SARS-CoV-2 replicase gene encodes two overlapping poly-
proteins for viral replication and transcription. The polyproteins un-
dergo extensive proteolytic processing that is largely carried out by Mpro 
to form functional polypeptides. Mpro plays a vital role in mediating the 
life cycle of SARS-CoV-2 and is an attractive target for antiviral drug 
design [121]. A fluorescence resonance energy transfer assay has been 
developed for high-throughput screening of Mpro inhibitors. Based on 
this method, 10,000 compounds, including FDA-approved drugs, clin-
ical trial/preclinical drug candidates and natural products, have been 
examined for their potency of inhibiting Mpro activity [121]. Ebselen, an 
organoselenium compound designed as a GPX1 mimic, was found to 
have the strongest inhibitory activity [121]. Ebselen covalently binds to 
sulfhydryl group of the Cys145 residue in the catalytic dyad of the 
protease. Consistently, quantitative real-time RT-PCR showed that 
ebselen was also the strongest antiviral compound in SARS-CoV-2 
infected Vero cells [121]. Like SARS-CoV-2 Mpro, the papain-like pro-
tease (PLpro) of SARS-CoV-2 is also a cysteine protease that is pivotal for 
virus replication by processing the viral polyprotein into mature, func-
tional subunits. In addition, SARS-CoV-2 uses PLpro to antagonize the 
host’s antiviral innate immune response hence it is another promising 
target for suppression. Ebselen was found to be a highly active inhibitor 
of SARS-CoV-2 PLpro via covalent bind of the selenium in ebselen with 
the sulfhydryl group of the Cys112 residue in the catalytic triad of the 
protease, with an inhibition constant in the low micromolar range 
[122]. 
4.6. Ebselen causes thiol oxidation of critical thiol-dependent pathogen 
enzymes 
Ebselen was found to be safe and effective in clinical trials for 
treatment of hearing loss and bipolar disorders [123–126]. It possesses 
anti-inflammatory, anti-oxidant and cytoprotective properties by acting 
mainly as a peroxiredoxin mimic and to a lesser extent as a glutathione 
peroxidase mimic to scavenge hydrogen peroxide and peroxynitrite in 
mammalian cells [127]. In addition to its canonical antioxidant roles, 
ebselen is also viewed as a thiol-peroxidase mimic causing thiol oxida-
tion [123,127]. Ebselen induces cellular apoptosis through rapid 
depletion of intracellular thiols [128,129] and is a superfast thioredoxin 
oxidant [130]. It also inhibits a number of thiol-dependent enzymes by 
targeting their critical thiol residues [131–133]. The inhibition can be 
prevented by the addition of reducing agents such as dithiothreitol. 
Ebselen has been found to have therapeutic potential against many in-
fectious diseases. In most cases, ebselen acts as a covalent inhibitor of 
numerous thiol-dependent enzymes or functional proteins in various 
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pathogens [134–146]. The selenol derived from ebselen is reactive to 
cysteine residues in proteins. The ebselen-mediated inhibition is usually 
dependent on the selenosulfide formed between ebselen and protein 
thiols [127]. Notably, ebselen has been found to be active in 193 out of 
1023 drug screenings [146], revealing its promiscuous binding property 
and limited druggability. However, ebselen as a paradigm lead com-
pound for inhibiting Mpro activity of SARS-CoV-2 and suppressing the 
life cycle of SARS-CoV-2 among 10,000 compounds examined [121], 
suggests that redox-active selenium compounds formed in vivo might 
participate in inhibiting SARS-CoV-2 replication since this class of se-
lenium species can behave as ebselen by reacting with sulfhydryl group 
of protein cysteine residues (see below). 
4.7. Redox-active selenium metabolites are involved in the anti-viral 
action of selenium in mice and humans 
Steinbrenner et al. have predicted that effective selenium interven-
tion in infectious diseases and cancers would have a similar dose range 
[42]. Cancer-preventive effects of selenium were more likely to be found 
at supranutritional dose levels (1–2 μg selenium/g diet) in numerous 
animal studies. The underlying mechanism has mainly been ascribed to 
the accumulation of redox-active selenium compounds at supranutri-
tional dose levels, which largely exceed the requirement for selenopro-
tein biosynthesis (0.1 μg selenium/g diet) [147–151]. Anti-viral effects 
of selenium in animals have never been studied at such high dose levels. 
However, a study investigating the dose-response relationship of sele-
nite against H1N1 influenza virus up to a maximum of 0.5 μg selenium/g 
Fig. 2. Hypothesised interaction of selenium com-
pounds with SARS-CoV-2 consisting of cycling of 
redox-active selenium compounds in various cells 
(lower panel) and the presence of volatile redox- 
active selenium compounds in the lung (upper 
panel). GS-Se-SG, selenodiglutathione; CH3SeOH, 
methylseleninic acid; CH3SeSeCH3, dimethyldisele-
nide; H2Se, hydrogen selenide; GS-SeH, glutathione 
selenopersulfide; CH3SeH, methylselenol; GSH, 
glutathione; GR, GSH reductase; GRX, glutaredoxin; 
TXN, thioredoxin; TXNRD, TXN reductase.   
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diet, suggests that redox-active selenium metabolites play a role in the 
anti-viral action of selenium [152]. While H1N1 influenza virus resulted 
in a low survival percentage in selenium-deficient mice, i.e. 25%, the 
survival percentage was increased to 41%, 50%, 75% and 75% in mice 
that consumed diets long-term containing 0.2, 0.3, 0.4 and 0.5 μg sele-
nium/g, respectively, in the form of selenite, with a Pearson r as high as 
0.97 (p < 0.01), linking survival percentage to dietary selenium levels 
[152]. Moreover, the therapeutic effect of a short course of high-dose 
selenium in patients with “epidemic hemorrhagic fever” (one of 
several illnesses caused by hantavirus infection) also implies that 
redox-active selenium metabolites are involved in the anti-viral action of 
selenium [46]. Specifically, cases of “epidemic hemorrhagic fever” were 
treated exclusively by multiple oral doses of 2 mg sodium selenite/d 
(913 μg selenium/d) in the first 9 days of hospitalisation; compared to 
the untreated control, the mortality dropped from 100% to 36% in the 
fulminant type (p = 0.013 by Fisher’s exact test) [46]. Given the 
aforementioned high correlation between dietary selenium (from 
nutritional to apparently supranutritional levels) and survival percent-
age following viral infection in mice [152], the dramatic reduction of 
hantavirus-associated fatality rate in humans after the treatment with a 
pharmacological dose of selenite [46], and the fact that the cure rate of 
COVID-19 patients continued to rise beyond the selenium intake 
required to optimise selenoprotein requirements [7], it is anticipated 
that redox-active metabolites of supranutritional selenium could also 
inhibit the Mpro of SARS-CoV-2. 
4.8. Redox-active selenium species may have the potential to react with 
SARS-CoV-2 Mpro 
Following a high intake of dietary selenium or supranutritional se-
lenium supplementation beyond the requirement for selenoprotein 
biosynthesis, small molecular weight selenium compounds are accu-
mulated [147–151]. Hydrogen selenide, methylselenol, dimethylsele-
nide and dimethyldiselenide are volatile small molecules and thus are 
likely to be found in the respiratory tract [147,153,154]. Some selenium 
compounds such as selenite and methylseleninic acid (a precursor of 
methylselenol) and many intermediates of selenium metabolism 
including selenodiglutathione, dimethyldiselenide and elemental sele-
nium nanoparticles have strong redox activity [155–157]. A common 
property of these selenium species is that they undergo redox cycling in 
the thioredoxin system, composed of thioredoxin and TXNRD, and the 
glutaredoxin-coupled glutathione system composed of glutathione, 
glutathione reductase and glutaredoxin, with the formation of ROS with 
the sacrifice of NADPH [158–160] (Fig. 2, low panel). Ganther proposed 
that thiol modification induced by redox-active selenium compounds 
might occur via modification of protein cysteine residues, leading to the 
formation of selenium adducts of the selenotrisulfide (S–Se–S) or sele-
nenylsulfide (S–Se) type or disulfides [161]. Evidence supporting this 
biochemical deduction includes, but is not limited to: (i) Selenite and 
selenodiglutathione are efficient oxidants of thioredoxin [162]; (ii) 
Selenite inactivates intracellular caspase-3 and inhibits the activity of 
purified recombinant caspase-3 by modification of a critical cysteine 
residue present within the active site [163]; (iii) Selenite also inactivates 
c-Jun N-terminal kinase by a direct modification of the Cys116 residue – 
the inhibitory action is abolished by replacement of Cys116 by serine or 
the addition of reducing agents [164]; (iv) Selenite also inactivates 
NF-κB by modification of the essential thiols of this transcription factor 
[106]; (v) Methylseleninic acid induces NAD(P)H:quinone 
oxidoreductase-1 expression through oxidizing thiols of Keap1 to 
release/activate NF-E2-related factor 2. This induction was abrogated by 
pre-treatment of cells with dithiothreitol [165]; (vi) Locally formed 
methylseleninic acid, following the oxidation of methylselenol by lipid 
hydroperoxides bound to protein kinase C, inhibits protein kinase C 
activity by oxidizing the vicinal thiols present within the catalytic 
domain [153,166–168]; (vii) Global redox modification of proteins by 
methylseleninic acid was characterized by a display thiol-proteomics 
approach [169]. Given that the Cys145 residue of the Mpro of 
SARS-CoV-2 is a vital target for inhibition and the excellent performance 
of ebselen in this context, it is conceivable that redox-active selenium 
compounds could react with HS-Cys145-Mpro (Fig. 2, low panel), leading 
to reduced replication, transcription and a truncated life cycle of 
SARS-CoV-2. 
4.9. The selenium metabolite, methylseleninic acid, may accumulate in 
SARS-CoV-2 infected cells 
Gopalakrishna et al. proposed an oxidant-associated sequestration of 
methylselenol in cells [153]. In normal cells with lower levels of oxi-
dants, volatile methylselenol is not oxidized to non-volatile methyl-
seleninic acid and thus is not retained by normal cells. In promoting 
pre-cancer cells with higher concentrations of oxidants, volatile meth-
ylselenol is retained after conversion to non-volatile methylseleninic 
acid. Viral respiratory infections are known to suppress antioxidant 
enzymes and induce ROS generating enzymes, resulting in enhanced 
ROS production and increased accumulation of oxidation products 
which, as discussed, may play a significant role in the inflammatory 
response to COVID-19 [170]. Under these circumstances, it is suggested 
that methylselenol is converted to methylseleninic acid. The accumu-
lated methylseleninic acid, in turn, might inactivate the Mpro of 
SARS-CoV-2 in infected cells by modifying the Cys145 residue of the 
Mpro. 
4.10. Volatile metabolites of selenium may gather in the lung 
It is known that dimethyselenide compounds are expelled in the 
breath [171]. Jüliger et al. found that of two known dimethyselenide 
compounds, namely dimethylselenide and dimethyldiselenide, dime-
thyldiselenide was generated more rapidly and copiously than dime-
thylselenide in cells subjected to methylseleninic acid treatment [172]. 
Dimethylselenide is more than 500-times less toxic than selenite in rats 
[173,174], implying that it is not a typical redox-active selenium com-
pound. However, like many diselenides, including naturally occurring 
selenocystine and synthetic diethyldiselenide, dipropyldiselenide and 
dibutyldiselenide [175] and the well-characterized diphenyldiselenide 
[176], dimethyldiselenide is also a redox-active selenium compound 
that generates ROS in the presence of glutathione [156]. The released 
dimethyldiselenide, in combination with methylselenol and hydrogen 
selenide from various cell types in many tissues, could conceivably 
gather in the lung, the main battlefield of viral respiratory infections, to 
inhibit the Mpro of SARS-CoV-2 (Fig. 2, upper panel). It is plausible that 
volatile redox-active selenium compounds formed in vivo following high 
dietary intake of selenium or high-dose selenium supplementation could 
constitute a defence against COVID-19 in the lung. 
5. Concluding remarks 
Most (though not all [177]) studies have demonstrated that selenium 
deficiency leads to increased host-susceptibility to viral infections. 
However, it is important to keep in mind that the effects of selenium 
deficiency on a virally-infected host may depend on the type of pa-
thology induced. 
With regard to effects that are likely to be primarily mediated 
through host selenoproteins, there is considerable evidence that a dys-
regulated innate immune system and cytokine release have the capacity 
to worsen COVID-19 [67–69]. In the elderly, who are particularly at risk, 
selenium deficiency is correlated with higher circulating inflammatory 
cytokines [91]. Published data support the hypothesis that selenium 
adequacy prevents excessive cytokine activation in infectious, inflam-
matory and oncological models [82–91]. In some cases, 
supra-therapeutic selenium contributed to enhanced adaptive immunity 
by reinvigorating cytotoxic cells and moderating the release of inflam-
matory cytokines by the innate immune system [14,58]. The presence of 
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SELENOS polymorphisms that directly influence cytokine production is 
particularly telling [24]. The promising results of selenium supple-
mentation shown in critically-ill patients may have resulted from these 
complex immunomodulatory actions. 
Further analysis of immunological phenomena in COVID-19, strati-
fied by baseline selenium status, would be valuable. Whether supple-
mentation of selenium during SARS-COV-2 infection could confer a 
survival benefit by dampening an overwhelming immune response is an 
important consideration for future clinical trials. 
Based on all the evidence described above, both selenoproteins and 
redox-active selenium species (that mimic selenium-containing ebselen 
[121]) in the selenium metabolic pool could employ their separate 
mechanisms to attenuate virus-triggered oxidative stress, excessive in-
flammatory responses and immune-system dysfunction, thus improving 
the outcome of SARS-CoV-2 infection, as hypothesised in Fig. 3. A 
possible area for future study will be the strategies that viruses use to 
interfere with selenium-based host-protective mechanisms. 
Finally, it is well documented that there is a narrow dose range 
spanning the beneficial and adverse effects of selenium [3,11]. In gen-
eral, the current literature discourages selenium-adequate individuals 
from increasing their selenium intake to a level normally associated with 
toxicity that would markedly increase the formation of redox-active 
selenium species [3,11,178]. However, for COVID-19 disease, we have 
identified an association between more-than-adequate selenium inta-
ke/status and higher cure rate [7]. The acute infection phase in 
COVID-19 is only a few weeks in typical cases, which is comparable to 
the time-frame over which daily doses of 1 mg selenium (as selenite) 
have been used in sepsis and critical care applications [105,179,180]. 
Based on such precedents, over a similar time-frame, a comparable 
supranutritional dose of selenium would be very unlikely to result in 
toxicity in COVID-19 patients and might be beneficial in those with 
moderate-to-severe symptoms. However, the potential benefit of such a 
strategy would need to be tested clinically, preferably in a randomised, 
controlled trial. 
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